Beta blockers may increase progression-free survival (PFS) in
HER2-negative and triple-negative breast cancer patients, according to
investigators in Canada and Uruguay, who reported that patients who received the
agents experienced a longer median PFS than those without the treatment.
The investigators conducted a retrospective analysis of data from the ROSE/TRIO-012 trial, a multinational, double-blind, Phase III trial that randomly assigned 1,144 patients with HER2-negative advanced